Giuseppe Scalabrino

Dr. Giuseppe Scalabrino

Department of Biomedical Sciences, University of Milan, 20122 Milan, Italy
orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications


1 June 2006 in Trends in Molecular Medicine
Verified
Journal Article
Closed access
Giuseppe ScalabrinoGiuseppe Scalabrino
Giuseppe Scalabrino
MPMaddalena Peracchi
Maddalena Peracchi

1 August 2001 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
MPM. Peracchi
M. Peracchi
FCF. Bamonti Catena
F. Bamonti Catena
MPM. Pomati
M. Pomati
MFM. De Franceschi
M. De Franceschi
Giuseppe ScalabrinoGiuseppe Scalabrino
Giuseppe Scalabrino

23 November 2004 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
Giuseppe ScalabrinoGiuseppe Scalabrino
Giuseppe Scalabrino
MCMarinella Carpo
Marinella Carpo
FBFabrizia Bamonti
Fabrizia Bamonti
SPSimona Pizzinelli
Simona Pizzinelli
CDCarla D'AVino
Carla D'AVino
MPMaddalena Peracchi
Maddalena Peracchi

5 November 2020 in Cellular and Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
Giuseppe ScalabrinoGiuseppe Scalabrino
Giuseppe Scalabrino
This article reviews the wealth of papers dealing with the different effects of epidermal growth factor (EGF) on oligodendrocytes, astrocytes, neurons, and neural stem cells (NSCs). EGF induces the in vitro and in vivo proliferation of NSCs, their migration, and their differentiation towards the neuroglial cell line. It interacts with extracellular matrix components. NSCs are distributed in different CNS areas, serve as a reservoir of multipotent cells, and may be increased during CNS demyelinating diseases. EGF has pleiotropic differentiative and proliferative effects on the main CNS cell types, particularly oligodendrocytes and their precursors, and astrocytes. EGF mediates the in vivo myelinotrophic effect of cobalamin on the CNS, and modulates the synthesis and levels of CNS normal prions (PrPCs), both of which are indispensable for myelinogenesis and myelin maintenance. EGF levels are significantly lower in the cerebrospinal fluid and spinal cord of patients with multiple sclerosis (MS), which probably explains remyelination failure, also because of the EGF marginal role in immunology. When repeatedly administered, EGF protects mouse spinal cord from demyelination in various experimental models of autoimmune encephalomyelitis. It would be worth further investigating the role of EGF in the pathogenesis of MS because of its multifarious effects.